Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus

Clinical Infectious Diseases

Volumn 50, Issue 5, 2010, Pages 707-714

  Ng, Sophia ^a   Cowling, Benjamin J ^a   Fang, Vicky J ^a   Chan, Kwok Hung ^a   Ip, Dennis K M ^a   Cheng, Calvin K Y ^a   Uyeki, Timothy M ^b   Houck, Peter M ^c   Malik Peiris, J S ^a   Leung, Gabriel M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c NATIONAL CENTER FOR PREPAREDNESS DETECTION AND CONTROL OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; OSELTAMIVIR; STEROID;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HOUSEHOLD; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROAT CULTURE; VIRUS CULTURE; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FAMILY CHARACTERISTICS; FAMILY HEALTH; HUMANS; INFANT; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NOSE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; PHARYNX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME; VIRUS SHEDDING; YOUNG ADULT;

EID: 76749102845     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650458     Document Type: Article

References (24)

1. World Health Organization. Acute respiratory infections (update February 2009). http://www.who.int/vacdne-research/diseases/ari/en/print.html. Accessed 5 April 2009.
2. Centers for Disease Control and Prevention. CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-09 influenza season, http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum= 00279. Accessed 5 April 2009.
3. Centers for Disease Control and Prevention. Interim guidance on antiviral recommendations for patients with novel influenza A (H1N1) virus infection and their close contacts, http://cdc.gov/h1n1flu/recommendations.htm. Accessed 26 June 2009.
4. Jefferson TO, Demicheli V, Di Pietrantoni C, Jones M, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006;3:CD001265.
5. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-754
6. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment, with or without postexposure prophylaxis. J Infect Dis 2004; 189:440-449
7. Halloran ME, Hayden FG, Yang Y, Longini IM Jr, Monto AS. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 2007; 165:212-221
8. Cauchemez S, Carrat F, Viboud C, Valieron AJ, Boelle PY. A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. Stat Med 2004; 23:3469-3487
9. Ferguson NM, Cummings DA, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005; 437:209-214
10. Cowling BJ, Fung ROP, Cheng CKY, et al. Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households. PLoS One 2008; 3:e2101.
11. Cowling BJ, Chan KH, Fang VJ, et al. Face masks and hand hygiene to prevent influenza transmission in households: a cluster randomized, controlled trial. Ann Intern Med 2009; 151:437-446
12. Collett D. Modelling survival data in medical research. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC, 2003.
13. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19:716-723
14. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B 1976; 38: 290-295
15. Cowling BJ, Muller MP, Wong IO, et al. Alternative methods of estimating an incubation distribution: examples from severe acute respiratory syndrome. Epidemiology 2007; 18:253-259
16. Lindsey JC. Tutorial in biostatistics methods for interval censored data. Stat Med 1998; 17:219-238
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
18. Donner A, Klar N. Design and analysis of cluster randomization trials in health research. London: Arnold, 2000.
19. Cheng PK, Leung TW, Ho EC, et al. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 2009; 15:966-968
20. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235.
21. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
22. Kawai N, Ikematsu H, Iwaki N, et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect 2009; 59:207-212
23. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008; 8:727-733
24. Wu JT, Riley S, Fraser C, Leung GM. Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Med 2006; 3:e361.